Greater Sensitivity ELISA for HIV by Photoillumination

通过光照明法检测 HIV 的 ELISA 灵敏度更高

• 批准号: 6338194
• 负责人: MICHAEL M MUEHLEMANN
• 金额: $ 14.02万
• 依托单位: ILLUMINATION TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-30 至 2002-06-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6338194
• 关键词: AIDS /HIV test; Streptococcus pyogenes; aniline; biomarker; biotechnology; blood chemistry; colorimetry; diagnosis design /evaluation; diagnosis quality /standard; diagnostic tests; enzyme linked immunosorbent assay; horseradish peroxidase; human immunodeficiency virus 1; human tissue; immunologic assay /test; photochemistry; reagent /indicator; technology /technique development

DESCRIPTION (provided by the applicant): Based on a preliminary tests, Illumination Technologies has demonstrated a 26-fold improvement in the detection sensitivity of HIV p24 on pedigreed human plasma samples using a commercial ELISA assay manufactured by DuPont. The company is determined to further develop the BioPhotTM technology (illuminator and amplification reagent) and proposes to expand the testing of the Dupont HIV p24 assay to a more statistically significant sample set, under the continued direction of Dr. Poiesz at the SU'NY Health Science Center. The goal for this round of tests is to establish a statistically significant data set, using normal human plasma samples, for determining the absolute sensitivity cut-off and therefore the calculated sensitivity improvement. The BioPhotTM technology has also demonstrated increased sensitivity for other viral, bacterial and tumor marker assays that utilize I-IRP conjugates and OPD for color development. These results support the theoretical basis suggesting that BioPhotTM is an enabling or platform technology. Preliminary evidence suggests that the BioPhotTM platform can be developed for a wide range of applications that utilize HRP conjugates and OPD for color development. Further parallel efforts using commercial assays for the detection of the Strep bacterium S. pyogenes are proposed to preliminarily demonstrate platform invariance PROPOSED COMMERCIAL APPLICATION: More sensitive screening assyas based on industry standard ELISA kits for the detection of harmful pathogens including HIV, Hepatitis, E. Coli, Samonella and a host of tumor markers.

描述（由申请人提供）：根据初步测试， 照明技术公司已经证明， 用一种新的方法检测HIV p24对人血浆样本的灵敏度 由DuPont制造的商业ELISA测定。该公司决心 进一步开发BioPhotTM技术（照明和放大 试剂），并建议将Dupont HIV p24检测试剂盒的检测范围扩大到 更具有统计学意义的样本集，在博士的继续指导下。 在SU 'NY健康科学中心的Poiesz。这一轮测试的目标是 使用正常人血浆建立具有统计学意义的数据集 样品，用于确定绝对灵敏度截止值， 计算的灵敏度提高。 BioPhotTM技术还证明了对其他生物样品的灵敏度提高。 利用I-IRP缀合物和OPD的病毒、细菌和肿瘤标志物测定 用于显色。这些结果支持的理论基础， BioPhotTM是一种赋能技术或平台技术。初步证据 表明BioPhotTM平台可以开发用于广泛的 利用HRP结合物和OPD进行显色的应用。进一步 使用商业检测方法检测链球菌 细菌S.化脓菌被提出来初步展示平台 不变性 拟定商业应用： 基于行业标准ELISA试剂盒的更灵敏的筛查系统，用于检测有害病原体，包括HIV、肝炎、E。大肠杆菌沙门氏菌和一系列肿瘤标记。